Fatty liver disease: Should you be tested?
Weight-loss drug may lower risk of heart attacks and infections
Testosterone therapy without evidence of deficiency may boost heart risk
Even a little exercise linked with lower stroke risk in people with afib
Antihistamines may not offer meaningful relief from eczema symptoms
What to eat on the DASH diet
Tricep workouts you can do at home
FDA approves first mRNA-based flu vaccine
Migraine: How it's diagnosed and what that means
Mindfulness practices to reduce stress and improve focus
Medical Tests & Procedures Archive
Articles
Fasting before lipid test usually unnecessary
Most people don't need to fast before a lipid test because the difference between LDL cholesterol values when fasting or not fasting is very small. But people who have had high triglyceride levels should fast prior to the test.
Is it safe to stop aspirin a year after a stent?
After a heart attack or stent placement, people typically take a combination of aspirin and another antiplatelet drug. After one year, the new standard practice is to stop the aspirin, in contrast to the previous practice of stopping the other drug.
Lipoprotein(a): An update on testing and treatment
High levels of Lp(a)-a fatty particle similar to LDL cholesterol-may double or triple a person's risk of a heart attack. About one in five adults may have elevated levels, which also raises the risk of stroke and aortic stenosis. Unlike LDL, which rises with age and is influenced by diet and exercise, Lp(a) remains largely constant over a person's lifetime, so a one-time test suffices for screening. Lp(a) testing is becoming more common now that five promising new Lp(a) therapies are in development.
Let's not call it cancer
Roughly one in six men will be diagnosed with prostate cancer at some point in their lives, but these cancers usually aren't life-threatening. The least risky form of the disease occurs frequently with age, will not metastasize to other parts of the body, and it doesn't require any immediate treatment. So, should it even be called cancer?
A liquid biopsy for metastatic prostate cancer
Researchers are developing tools for predicting how fast prostate cancer might progress; among the most promising are those that count circulating tumor cells (CTCs) in blood samples. Research shows that high CTC counts predict poorer survival and faster disease progression. But they are also predictive for early-stage metastatic prostate cancer that still responds to hormonal therapy.
Transperineal prostate biopsies linked with lower infection risk
In a 2024 study, transperineal prostate biopsies were less likely to cause infections than traditional transrectal biopsies. Transperineal biopsies retrieve tissue samples using a thin needle inserted through the skin between the scrotum and rectum.
Pap smears or self-swabs?
Pap tests, the mainstay screening method to detect cervical cancer, are uncomfortable for some women. In mid-2024, the FDA approved a new self-swab test that can detect human papillomavirus, which causes most cases of cervical cancer. The self-swab test collects cells from the vaginal wall instead of the cervix. Clinicians guide women on how to perform the test in a doctor's office. The self-swab method offers women several benefits, including comfort, accuracy, and potentially greater access to screening.
Could imaging scans replace biopsies during prostate cancer screening?
Abnormal results on a prostate-specific antigen (PSA) screening test for cancer are typically followed by a systematic biopsy. But systematic biopsies can be problematic, and researchers are seeking alternatives. A large European study provides encouraging evidence favoring a different approach that uses MRI instead of biopsy.
New guidelines released for vitamin D testing and supplementation
Updated guidelines say adults don't need routine testing of vitamin D levels. However, they should aim for daily vitamin D intake of 600 international units (IU) until age 70, and 800 IU after that either through vitamin D-fortified foods or a supplement of up to 1,000 IU.
FDA approves blood test for colorectal cancer screening
In 2024, the FDA approved a blood test called Shield as a screening method for colorectal cancer. The test detects 83% of colorectal cancers, but only 13% of precancerous polyps. The FDA approval means that now many insurance plans will pay for the test.
Fatty liver disease: Should you be tested?
Weight-loss drug may lower risk of heart attacks and infections
Testosterone therapy without evidence of deficiency may boost heart risk
Even a little exercise linked with lower stroke risk in people with afib
Antihistamines may not offer meaningful relief from eczema symptoms
What to eat on the DASH diet
Tricep workouts you can do at home
FDA approves first mRNA-based flu vaccine
Migraine: How it's diagnosed and what that means
Mindfulness practices to reduce stress and improve focus
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!
Sign Up